Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
第一作者单位:[1]Lungenclin Grosshansdorf Gmbh, Grosshansdorf, Germany[2]Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany[3]Deutsch Zentrum Lungenforsch DZL, Airway Res Ctr North Arcn, Neuherberg, Germany
推荐引用方式(GB/T 7714):
Rabe K. F.,Martinez F. J.,Ferguson G. T.,et al.Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis[J].PNEUMOLOGIE.2021,75:S12-S12.doi:10.1055/s-0041-1723285.
APA:
Rabe, K. F.,Martinez, F. J.,Ferguson, G. T.,Wang, C.,Singh, D....&Dorinsky, P..(2021).Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis.PNEUMOLOGIE,75,
MLA:
Rabe, K. F.,et al."Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis".PNEUMOLOGIE 75.(2021):S12-S12